Cargando…

Bcl-2, Bcl-xL, and p-AKT are involved in neuroprotective effects of transcription factor Brn3b in an ocular hypertension rat model of glaucoma

PURPOSE: Brn3b is a class IV POU domain transcription factor that plays an important role in the development of retinal ganglion cells (RGCs), RGC survival, and particularly axon growth and pathfinding. Our previous study demonstrated that recombinant adenoassociated virus serotype 2 (rAAV-2)–mediat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Phatak, Nitasha R., Stankowska, Dorota L., Krishnamoorthy, Raghu R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Vision 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990101/ https://www.ncbi.nlm.nih.gov/pubmed/27587945

Ejemplares similares

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

ΔN-Bcl-xL, a therapeutic target for neuroprotection
por: Park, Han-A, et al.
Publicado: (2017)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
por: Follis, Ariele Viacava, et al.
Publicado: (2018)

Nrz but not zBcl-xL antagonizes Bcl-wav pro-apoptotic activity in zebrafish
por: Prudent, Julien, et al.
Publicado: (2014)

Disruption of Bcl-2 and Bcl-xL by viral proteins as a possible cause of cancer
por: Alibek, Kenneth, et al.
Publicado: (2014)

Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity
por: Park, Han-A, et al.
Publicado: (2017)

Dynamics of Bcl-xL in Water and Membrane: Molecular Simulations
por: Maity, Atanu, et al.
Publicado: (2013)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

The Role of Bcl-xL Protein Research in Veterinary Oncology
por: Pawlak, Aleksandra, et al.
Publicado: (2020)

Bcl-xL activity influences outcome of the mitotic arrest
por: Suleimenov, M., et al.
Publicado: (2022)

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Lv, Dongwen, et al.
Publicado: (2021)

Bioinformatic Analysis of the BCL-xL/BCL2L1 Interactome in Patients with Pancreatic Cancer
por: Magouliotis, Dimitrios E., et al.
Publicado: (2022)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
por: Li, Ji-Yu, et al.
Publicado: (2012)

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Zhang, Yiru, et al.
Publicado: (2018)

Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Shang, Enyuan, et al.
Publicado: (2018)

Bcl-2/Bcl-xL inhibitor ABT-263 overcomes hypoxia-driven radioresistence and improves radiotherapy
por: Ritter, Violetta, et al.
Publicado: (2021)

Bcl-xL affects the development of functional CD4 Tregs
por: Sharabi, Amir, et al.
Publicado: (2010)

Bcl-xL inhibition - a novel strategy for glioma therapy
por: Karpel-Massler, Georg, et al.
Publicado: (2016)

Retromer facilitates the localization of Bcl-xL to the mitochondrial outer membrane
por: Farmer, Trey, et al.
Publicado: (2019)

Effects of Cardiolipin on the Conformational Dynamics of Membrane-Anchored Bcl-xL
por: Tyagi, Vivek, et al.
Publicado: (2021)

Functional impact of cancer patient‐associated Bcl‐xL mutations
por: Zhang, Tiantian, et al.
Publicado: (2020)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Oral administration of a dual ET(A)/ET(B) receptor antagonist promotes neuroprotection in a rodent model of glaucoma
por: Kodati, Bindu, et al.
Publicado: (2022)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Praf2 Is a Novel Bcl-xL/Bcl-2 Interacting Protein with the Ability to Modulate Survival of Cancer Cells
por: Vento, Maria Teresa, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5m37tj79nnpfr8ilht0qc4p8ff